The Prolonged Use of Topiramate for Preventing Migraine Headaches

PHASE3CompletedINTERVENTIONAL
Enrollment

834

Participants

Timeline

Start Date

November 30, 2003

Study Completion Date

August 31, 2006

Conditions
Migraine
Interventions
DRUG

Topiramate

topiramate treatment started with one tablet per day, taken in the evening, for the first 7 days of the OL phase. Each tablet contained 25 mg topiramate. After one week, the dose was raised to two tablets per day: one tablet was taken in the morning, the other in the evening.

DRUG

Topiramate - Placebo

the trial medication consisted of topiramate 25 mg tablets or matching placebo tablets which were identical in appearance, taste and smell. DB randomisation phase (after the 26-weeks OL phase) were randomly allocated (1:1) to one of the two treatment groups (topiramate or placebo). The randomisation took place at Visit 6 (Week 26)

Trial Locations (68)

Unknown

Innsbruck

Linz

Antwerp

Charleroi

Leuven

Liÿge

Pleven

Plovdiv

Sofia

Hradec nad Svitavou

Prague

Aabenraa

Esbjerg

Glostrup Municipality

Kÿbenhavn K

Odense

Colombes

Lille

Nice

Paris

Rouen

Voiron

Berlin

Essen

München

Mÿnster

Athens

Thessaloniki

Budapest

Budapest Na

Miskolc

Szeged Na

Cork

Dublin

Bodø

Oslo

Trondheim

Gdansk

Krakow Malopolska

Lodz

Mosina Poland

Poznan

Poznan Poland

Warsaw

Coimbra

Lisbon

Porto

Moscow

Saint Petersburg

Riyadh

Ljubljana

Maribor

Madrid

Biel/Bienne

Sankt Gallen

Zurich

Bursa

Istanbul

Brighton

Glasgow

Helensburgh

Leicester

Newcastle upon Tyne

Northampton

Stoke-on-Trent

Sunderland

Surrey

York

All Listed Sponsors
lead

Janssen Pharmaceutica N.V., Belgium

INDUSTRY

NCT00216619 - The Prolonged Use of Topiramate for Preventing Migraine Headaches | Biotech Hunter | Biotech Hunter